SmartGateVC

Ashot Arzumanyan

Ashot Arzumanyan is a seasoned venture capitalist and co-founder of SmartGateVC, a Los Angeles seed fund backing 33 science-driven startups. His portfolio includes SuperAnnotate, Deep Origin and ThirdLaw Molecular, reflecting his focus on frontier tech at the intersection of AI, biology and advanced materials.

Our brains will ultimately plug into the cloud with no screens or phones. In the race with ever smarter AI, the only way humanity stays relevant is by augmenting ourselves. That vision reads like science fiction, yet its feet stand on solid med-tech ground: minimally invasive electrodes, neuromodulators and chemical sensor arrays are already waiting to be reimbursed in U.S. clinics, addressing a market of roughly $400 billion across 10 million patients. Every shipment of those devices is going to expand the safety dossiers, patents and proprietary datasets that will one day carry full scale Brain Computer Interfaces (BCIs) and human AI copilots down the track.

Surgically implanted electrodes already let volunteers with tetraplegia click a cursor, drive a wheelchair, or synthesize speech. Neuralink’s first patient moved a cursor just six weeks after his January 2024 implant. Early adopters matter because they create the safety dossiers, reimbursement codes and manufacturing playbooks every later application will inherit. Current enabling implants list around $60,000 apiece—already within the reimbursement range for deep-brain stimulators.

Engineering for Scale and Accessibility

Catheter-delivered BCIs promise similar results without a craniotomy. Synchron’s vascular Stentrode was placed through a jugular vein in roughly twenty minutes and transmitted digital motor outputs in all COMMAND-study participants. Next-generation devices, such as Vonova’s grid for the superior sagittal sinus, aim to match cortical-surface resolution by 2026. Robotic “sewing machines” could thread micro-filaments before the decade is out, recasting BCIs as routine interventional radiology.

Signaling how quickly these clinical systems can intersect mainstream tech, Apple announced inMay 2025 that its accessibility team is partnering with Synchron to let the Stentrode drive native iPhone, iPad and Vision Pro controls.

In 2024, U.S. medical device startups raised $7.5 billion across 421 deals; neurology captured about $1.2 billion (≈16%), led by BCI and neuro-stimulation rounds. Deal size skews large: Saluda Medical’s $150 million Series F for closed-loop spinal stimulation dwarfs the median digital health check.

BCI firms still consume the most capital per company—hardware plus custom silicon. But investors treat catheter-delivered access devices and neuromodulators as parallel bets on the same ultimate prize: real-time, high-bandwidth read-write with the central nervous system.

Mapping the Neuro-Tech Investment Stack

Strategic buyers for neuro-tech extend beyond cortical-implant majors to cardiac-device giants that already sell stimulators, as well as pharma companies seeking closed-loop drug-delivery triggers. Medtronic’s $1.1 billion Intersect ENT buyout (drugeluting sinus implants) and Insightec’s $300 million late-stage round to advance focused ultrasound endpoints show the appetite for adjacent modalities. IPO windows typically open once recurring device revenue crosses ≈$50 million, regardless of whether the underlying modality is electrical, acoustic or biochemical.

In software, algorithms rule; in BCIs, hardware, biochemistry and material science rule. Competitive advantage accrues in four stacked layers, each harder to clone than the one above it:

1. Defended access hardware & materials: Catheter geometry, micrometer-pitch connectors and drug-resistant coatings that yield safety data no rival can replicate.

2. Closed-loop algorithms & data annuity: Proprietary signals feed software turning each implant into a SaaS handle.

Owning the data sourcing also means owning the follow-on software annuity that Morgan Stanley estimates at $10-20k per patient year

That inversion explains why BCI is rooted in atoms—not bits—and why teams need materials scientists alongside software engineers.

In the next ten years, devices that are delivered through catheters will allow stroke survivors to write messages just by thinking; smart deep-brain stimulators will help treat severe depression only when certain signals are detected; and special sensors will track brain tumor edges in real-time, helping to release medicine exactly where it's needed. Each milestone widens the regulatory, data and AI moat that will ultimately carry full-scale BCIs.

Near term, cash flowing indications are not optional—they are the runway. Ship devices that treat reimbursed conditions today, harvest proprietary signals tomorrow and lock in hardware moats no rival can clone. Nail the low hanging fruit now and the capital for full scale BCIs will follow.